BridgeBio Pharma Reports Strong Attruby Commercial Performance, Advances Multiple Phase 3 Programs, and Secures New Convertible Debt

summarizeSummary

BridgeBio Pharma's 2025 annual report details robust commercial success for Attruby, positive Phase 3 data for three pipeline drugs with planned 2026 regulatory submissions, and a recent $632.5 million convertible note offering to bolster liquidity and manage debt.

check_boxKey Events

• Strong Attruby Commercial Performance

  Net product revenue from Attruby (acoramidis) surged to $362.4 million in 2025, up from $2.9 million in 2024, following its FDA approval in November 2024 and European/Japanese approvals in early 2025. The product achieved 7,804 unique patient prescriptions and an estimated >25% new-to-brand prescription share in the U.S.

• Multiple Phase 3 Pipeline Successes

  The company announced positive Phase 3 topline results for infigratinib in achondroplasia (February 2026), encaleret in ADH1 (October 2025), and BBP-418 in LGMD2I/R9 (October 2025). Regulatory submissions (NDAs/MAAs) for these three candidates are planned for the second half of 2026 (infigratinib) and first half of 2026 (encaleret, BBP-418).

• New Convertible Notes Offering and Share Repurchase

  As a subsequent event, BridgeBio issued $632.5 million in 0.75% Convertible Senior Notes due 2033 on January 21, 2026. Approximately $82.5 million of the net proceeds were used to repurchase 1,081,825 shares of common stock, with the remainder intended for general corporate purposes and to settle future conversion obligations or repay a portion of the 2027 Notes.

• Significant Royalty Monetization

  In June 2025, the company sold certain royalty interests on net sales of acoramidis in the EU for $300.0 million in cash, providing substantial non-dilutive funding.

auto_awesomeAnalysis

This annual report highlights BridgeBio Pharma's significant transition to a commercial-stage company, driven by the successful launch and strong uptake of Attruby (acoramidis) in the U.S. and Beyonttra in Europe and Japan, generating $362.4 million in net product revenue in 2025. The company also reported positive Phase 3 results for three key pipeline candidates (infigratinib for achondroplasia, encaleret for ADH1, and BBP-418 for LGMD2I/R9), with regulatory submissions planned for 2026, signaling substantial future growth potential. Furthermore, the disclosure of a $632.5 million convertible note offering in January 2026, used in part for share repurchases and to address upcoming debt maturities, demonstrates proactive capital management and provides significant liquidity. While the company continues to incur net losses, these strategic advancements and successful commercialization efforts are critical for its long-term viability and represent a strong positive signal for investors.